A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol

BACKGROUND: Metastatic pancreatic cancer has a dismal prognosis, with a mean six-month progression-free survival of approximately 50% and a median survival of about 11 months. Despite intensive research, only slight improvements of clinical outcome could be achieved over the last decades. Hence, new...

Descripción completa

Detalles Bibliográficos
Autores principales: Hajda, Jacek, Lehmann, Monika, Krebs, Ottheinz, Kieser, Meinhard, Geletneky, Karsten, Jäger, Dirk, Dahm, Michael, Huber, Bernard, Schöning, Tilman, Sedlaczek, Oliver, Stenzinger, Albrecht, Halama, Niels, Daniel, Volker, Leuchs, Barbara, Angelova, Assia, Rommelaere, Jean, Engeland, Christine E., Springfeld, Christoph, Ungerechts, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574242/
https://www.ncbi.nlm.nih.gov/pubmed/28851316
http://dx.doi.org/10.1186/s12885-017-3604-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574242/
https://www.ncbi.nlm.nih.gov/pubmed/28851316
http://dx.doi.org/10.1186/s12885-017-3604-y

Ejemplares similares